GlassScriptPhysician profile
Justin Cohen
NPI 1700060704
$132,923.69
in general payments reported to CMS, 2019-2025
64 companies · $55K in 2025
The $55K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $3,441 · 2021: $3,539 · 2022: $6,126 · 2023: $28K · 2024: $36K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Long Term Medical Supply Or Device Loan: $35K · Consulting Fee: $11K · Food and Beverage: $8,560 · Travel and Lodging: $8,537 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,360.00 |
| Long Term Medical Supply Or Device Loan | $34,750.00 |
| Consulting Fee | $11,357.50 |
| Food and Beverage | $8,559.93 |
| Travel and Lodging | $8,536.60 |
| Education | $124.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $75,517.02 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Angiodynamics, INC. | $37,818.63 | 2022-2025 | Nanoknife |
| Dendreon Pharmaceuticals LLC | $3,717.88 | 2019-2025 | Provenge |
| Boston Scientific Corporation | $2,888.30 | 2019-2025 | Rezum Generator, Ams 800 Artificial Urinary Sphincter, Spaceoar Vue System - 10ml |
| Astrazeneca Pharmaceuticals LP | $1,799.77 | 2020-2025 | Imfinzi |
| Pfizer INC. | $1,769.32 | 2019-2025 | |
| Coloplast Corp | $636.58 | 2019-2025 | Speedicath |
| Abbvie INC. | $629.44 | 2021-2025 | Botox, Lupron Depot |
| Astellas Pharma US INC | $612.67 | 2019-2025 | Xtandi |
| Teleflex LLC | $611.12 | 2021-2025 | Urolift, Barrigel |
| Blue Earth Diagnostics | $521.45 | 2019-2025 | Posluma |
| Antares Pharma, INC. | $509.86 | 2019-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $478.17 | 2020-2025 | Keytruda, Lynparza |
| Urogen Pharma, INC. | $456.94 | 2022-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $379.15 | 2023-2025 | Gemtesa, Orgovyx |
Show all 63 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.